Latest Oncology News

Statin Use Is Not Associated With Improved Outcomes in Early HER2+ Breast Cancer

May 22nd 2025

Jax DiEugenio

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting

May 22nd 2025

Courtney Flaherty

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

FDA Votes Against Risk/Benefit Profile of Talazoparib Plus Enzalutamide for Non-HRR–Mutant mCRPC

May 21st 2025

Ashling Wahner

The FDA’s ODAC voted 8 to 0 against the risk/benefit profile of talazoparib in combination with enzalutamide for patients with non-HRR–mutant mCRPC.

How Unexpected Opportunities Shaped an Oncology Career Beyond the Clinic: With D. Ross Camidge, MD, PhD; and Lauren Meehan Machos, MPH

May 21st 2025

D. Ross Camidge, MD, PhD

Camidge and Machos discussed Machos' early career transition from pre-med to sales, to her role in building strategic partnerships with key opinion leaders in oncology.

Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences

May 21st 2025

Courtney Flaherty

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

Latest Oncology Videos

Key Takeaways and Future Directions: Genomic Assays in Breast Cancer Treatment

Key Takeaways From ASH 2024

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

Biomarker-Driven Decisions: Insights on Selecting Treatments in Advanced and Recurrent Endometrial Cance

Current Treatment Strategies in Pediatric R/R AML and ALL

Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

Leveraging Genomic Assays to Guide Treatment Decisions: Clinical Scenarios and Expert Perspectives

Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 and HER2CLIMB-05

Utilizing pCR, MPR, and Other Clinical Indicators to Guide Adjuvant Treatment Decisions in Early-Stage NSCLC

Identifying Appropriate Patients for PTCy as GVHD Prophylaxis in AlloHSCT

EBMT 2025 Highlight: Real-World GVHD Prophylaxis: - Insights From the GETH/TC Group Study

Leveraging MRD Testing to Guide Treatment Decisions in Early-Stage Resectable NSCLC

Navigating Third-Line Treatment Options in HER2+ Breast Cancer: ADC or TKI

Dr Vonderheide on Responses With RAS(ON) Inhibition in Preclinical Pancreatic Cancer Models

Dr Fakih on the FDA Approval of Retifanlimab for Advanced Anal Cancer

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

Dr Facon on the Rationale for Evaluating Isa-VRd in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

2025 ASCO Annual Meeting: The Show and After Show

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

Dr Kahl on the Rationale for Adding Bortezomib to BR Induction in MCL

Dr Maroto-Martin on the Preliminary Efficacy of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

Dr Sobh on the Therapeutic Potential of Selectively Targeting NSD2 in Multiple Myeloma

All Oncology News

Pola-R-CHP Is Associated With Improved 2-Year PFS Rates in Older Untreated DLBCL Population

May 21st 2025

Ashley Chan

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

Fragmented Care Does Not Affect Survival Outcomes for Retroperitoneal Sarcoma, Fox Chase Cancer Center Study Finds

May 21st 2025

Fox Chase Cancer Center

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Courtney Flaherty

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in Brain Cancer and CNS Diseases

May 21st 2025

Caroline Seymour

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC

May 21st 2025

Chris Ryan

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer

May 21st 2025

Megan Hollasch

Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.

TNBC Treatment Innovations Build on ADC Optimization, Provide Impetus for Individualized Care

May 21st 2025

Ashling Wahner

Alexis LeVee, MD, discusses ongoing phase 3 trials evaluating the first-line use of ADCs in both PD-L1–positive and –negative TNBC.

Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting

May 21st 2025

Kyle Doherty

Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.

FDA’s ODAC Votes in Favor of Risk/Benefit Profile of Subcutaneous Daratumumab for High-Risk Smoldering Myeloma

May 20th 2025

Ashling Wahner

The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20th 2025

Ashley Chan

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Multidisciplinary Collaboration and Immunotherapy Help Overcome Treatment Challenges in MCC

May 20th 2025

Kyle Doherty

Michael K. Wong, MD, PhD, FRCPC, discusses the landscape of Merkel cell carcinoma, including the role of immunotherapy and multidisciplinary treatment.

USC, UCLA Team Up for the World’s First-in-Human Bladder Transplant

May 20th 2025

USC Norris Comprehensive Cancer Center

Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders

Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma

May 20th 2025

Ashling Wahner

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL

May 20th 2025

Chris Ryan

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Acoustic Cluster Therapy Platform Boosts Tumor Shrinkage in Metastatic CRC

May 20th 2025

Jax DiEugenio

The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.

See All News